secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266842
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q3 net loss $306M; aficamten PDUFA on track; raises $750M convertible notes
--------------------------------------------------------------------------------

- Q3 net loss $306.2M ($2.55/share) vs $160.5M loss in prior year; includes $121.2M debt conversion expense.
- Cash, cash equivalents & investments $1.25B at Sep 30; raised $750M 1.75% convertible notes due 2031, used $402.5M to retire $399.5M of 2027 notes.
- PDUFA date for aficamten NDA remains Dec 26, 2025; commercial launch preparations on track.
- Updated FY2025 GAAP operating expense guidance to $680M-$700M (prior $670M-$710M).
- Total Q3 revenue $1.9M (vs $0.5M); R&D $99.2M, G&A $69.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/0001193125-25-266842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer